摘要
目的:探讨氟伐他汀联合普罗布考对急性冠脉综合征(ACS)患者血脂及血清超敏C-反应蛋白(hs-CRP)水平的影响。方法:收集ACS住院患者60例,随机分为A、B、C3组,每组20例,A组给予氟伐他汀40mg,1次/晚;B组给予氟伐他汀80mg,1次/晚;C组给予氟伐他汀40mg,1次/晚,并加用普罗布考250mg,2次/d。3组患者均于治疗前清晨空腹取血,测定hs-CRP和血脂水平,包括总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)。结果:治疗前3组间各项血脂指标及hs-CRP水平差异均无统计学意义(P>0.05)。治疗后C组血脂指标和hs-CRP水平较A组均降低(P<0.05),TC及HDL-C水平较B组均低(P<0.05),而TG及LDL-C水平与B组比较差异无统计学意义(P>0.05)。治疗后B、C组中TC、TG、LDL-C水平较治疗前降低(P<0.05或P<0.01);各组hs-CRP水平治疗前后差异均有统计意义(P<0.05)。结论:氟伐他汀联合普罗布考或大剂量氟伐他汀均能明显降低ACS患者血脂及hs-CPR水平,尤以氟伐他汀联合普罗布考效果更为显著。
Objective： To evaluate the effect of fluvastatin-probucol combined therapy on levels of serum lipid and se- rum high sensitivity C-reactive protein （hs-CRP） in patients with acute coronary syndrome （ACS）. Methods： A total of 60 pa- tients with ACS were randomly divided into three groups, A, B and C groups（n=20 for each group）. Patients of group A were taken fluvastatin 40 mg/d, patients of group B were taken fluvastatin 80 mg/d and patients of group C were taken fluvastatin 40 mg/d and 250 mg of probucol twice a day. The serum levels of total cholesterol （TC）, triglyeeride （TG）, low density lipopro- tein cholesterol （LDL-C）, high density ]ipoprotein cholesterol （HDL-C） and hs-CRP were examined before treatment in three groups. Results： There were no significant differences in serum levels of lipid and hs-CRP before treatment in three groups （P 〉 0.05）. After 3 months treatment, serum levels of lipid and hs-CRP were lower in group C than those of group A （P 〈 0.05）, levels of TC and HDL-C were lower in group C than those of group B （P 〈 0.05）. There were no significant differences in levels of TG and LDL-C between group C and group B （P 〉 0.05）. Compared with the pretreatment values, levels of TC and TG/LDL-C were significantly decreased in group B and group C after 3 months therapy （P 〈 0.05 or P 〈 0.01）. There was a significant difference in the level of hs-CRP before and after treatment in three groups （P 〈 0.05）. Conclusion： Combined treatment by fluvastatin and probucol or single high-dose fluvastatin therapy can significantly reduce serum levels of lipid and hs-CRP in ACS patiants. The combined treatment of fluvastatin with probucol could further strengthen the efficacy.
出处
《天津医药》
CAS
北大核心
2012年第6期560-562,共3页
Tianjin Medical Journal
